Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations

ScienceDaily
Aug 17, 2020, 7:17 pm154 pts
In a Phase II trial a combination targeted therapy achieved a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on EcoTopical

Massive EV discounts trigger a selloff before the $7,500 credit runs out 127

Vian Ruma, Indonesian activist, found dead. Aged 30. 126

How Indigenous fire stewardship continues to shape North American forests 125

In southeast Nigeria, pangolins hunted for meat, not scales, study finds 116

Why people displaced by conflict are particularly vulnerable to climate risks 114

Global decarbonization may raise poverty in low-income nations: Study urges targeted policies 113

Genesis is delaying this next-generation EV 109

UZH Device Searches for Light Dark Matter 106

About EcoTopical

Welcome to EcoTopical Your daily eco-friendly green news aggregator.

Leaf through planet Earths environmental headlines in one convenient place. Read, share and discover the latest on ecology, science and green living from the web's most popular sites.